Spin-off from EPFL developing precision gene therapies for Amyotrophic Lateral Sclerosis (ALS). ALS pathogenic mechanisms support that non-neuronal cells play a key role in this disease, through reshaping neuronal synaptic connections.
Products, services, technology
AVR-001 selectively and simultaneously co-targets SOD1 mutated ALS in both neurons and astrocytes. AVR-001 has been validated in rodent and non-human primate models. AVR-002 is designed to engage a novel "First-in Biology" neuroimmune pathophysiological mechanism and addresses all forms of ALS.
Cooperation possibilities
Bicistronic gene therapy platform co-targeting neurons and astrocytes from a single AAV.
- https://www.avriontx.com/
- Send an email
- Harald Petry
